Quantifying and Predicting the Effect of Exogenous Interleukin-7 on CD4⁺ T Cells in HIV-1 Infection

Rodolphe Thiebaut¹,²,³*, Julia Drylewicz⁴,⁵*, Mélanie Prague¹,²,³, Christine Lacabaratz⁶,⁷, Stéphanie Beq⁸, Ana Jarne¹,²,³, Thérèse Croughs⁸, Rafick-Pierre Sekaly⁹, Michael M. Lederman¹⁰, Irini Sereti¹¹, Daniel Commenges¹,²,³, Yves Lévy⁶,⁷,¹²

¹ INSERM, ISPED, Centre INSERM U897-Epidemiologie-Biostatistique, Bordeaux, France, ² Univ. Bordeaux, ISPED, Centre INSERM U897-Epidemiologie-Biostatistique, Bordeaux, France, ³ INRIA, SISTEM team, Bordeaux, France, ⁴ Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands, ⁵ Theoretical Biology and Bioinformatics, Department of Biology, Utrecht University, Utrecht, The Netherlands, ⁶ INSERM, Unité U955, Créteil, France, ⁷ Université Paris-Est, Faculté de Médecine, UMR-5955 Créteil, France, ⁸ CYTHERIS, Issy Les Moulineaux, France, ⁹ Vaccine and Gene Therapy Institute-Florida, Port St. Lucie, Florida, United States of America, ¹⁰ Case Western Reserve University/University Hospitals/Case Medical Center, Cleveland, Ohio, United States of America, ¹¹ National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America, ¹² AP-HP, Groupe Henri-Mondor Albert-Chenevier, Immunologie Clinique, Créteil, France

Abstract

Exogenous Interleukin-7 (IL-7), in supplement to antiretroviral therapy, leads to a substantial increase of all CD4⁺ T cell subsets in HIV-1 infected patients. However, the quantitative contribution of the several potential mechanisms of action of IL-7 is unknown. We have performed a mathematical analysis of repeated measurements of total and naive CD4⁺ T cells and their Ki67 expression from HIV-1 infected patients involved in three phase I/II studies (N=53 patients). We show that, besides a transient increase of peripheral proliferation, IL-7 exerts additional effects that play a significant role in CD4⁺ T cell dynamics up to 52 weeks. A decrease of the loss rate of the total CD4⁺ T cell is the most probable explanation. If this effect could be maintained during repeated administration of IL-7, our simulation study shows that such a strategy may allow maintaining CD4⁺ T cell counts above 500 cells/µL with 4 cycles or fewer over a period of two years. This in-depth analysis of clinical data revealed the potential for IL-7 to achieve sustained CD4⁺ T cell restoration with limited IL-7 exposure in HIV-1 infected patients with immune failure despite antiretroviral therapy.

Introduction

Human Immunodeficiency virus (HIV) infection is characterized by a profound depletion of CD4⁺ T cell numbers and function. Immune restoration with combination antiretroviral therapies (cART) has substantially improved patients’ outcomes. Unfortunately, this restoration may be delayed, notably in patients starting treatment late, and/or incomplete, despite control of the viral replication [1]. Hence, immune therapy may be a complementary intervention to accelerate or improve immune restoration. Interleukin-7 (IL-7) is a cytokine produced by non-narrow-derived stromal and epithelial cells and is required for the development and persistence of T cells in the periphery [2,3]. IL-7 may enhance thymopoiesis [4–6], as well as thymic-independent peripheral proliferation of recent thymic emigrants [7–9] and of more mature T cells [7,9] even in the absence of cognate antigen [9–11]. Improved cell survival has also been shown in vivo [11–15]. In HIV-infected patients, a strong inverse correlation has been observed between plasma IL-7 levels and CD4⁺ T cell numbers as well as with CD4⁺ T cell reconstitution after initiation of antiretroviral therapy [16,17–19]. Increased levels of IL-7 during lymphopenia are thought to be mainly the consequence of a decreased receptor-mediated clearance of IL-7 as the availability of receptors diminishes [20]. In addition, the IL-7 signaling on IL-7 receptor-a-positive (IL-7Ra⁺) dendritic cells in lymphopenic settings may diminish the homeostatic proliferation of CD4⁺ T cells [21]. A recent study has suggested that the remaining chronic inflammation in treated HIV-infected patients due to exposure to IL-1β and IL-6 may decrease T-cell sensitivity to IL-7 and therefore a reduced CD4⁺ T cell reconstitution [22]. Recent analyses of lymph node tissues have shown that collagen deposition may restrict T-cell access to IL-7, resulting in apoptosis and depletion of T cells [23]. This in turn leads to decreased production of lymphotoxin B, a trophic factor for reticuloendothelial cells, leading to their demise and loss of IL-7 producing cells. In summary, the IL-7 effect on CD4⁺ T cell homeostasis is highly compromised in HIV infection [24].

The beneficial effect of administration of IL-7 on T cell homeostasis in patients with refractory cancer [9], in SIV infected macaques [15,25,26] and HIV infected individuals has been shown through several early trials [27,28] and observational studies [29]. However, before proceeding with phase II and III trials, several questions remain. From a mechanistic standpoint,
HIV infection is characterized by a decrease of CD4+ T-lymphocytes in the blood. Whereas antiretroviral treatment succeeds to control viral replication, some patients fail to reconstitute their CD4+ T cell count to normal value. IL-7 is a promising cytokine under evaluation for its use in HIV infection, in supplement to antiretroviral therapy, as it increases cell proliferation and survival. Here, we use data from three clinical trials testing the effect of IL-7 on CD4+ T-cell recovery in treated HIV-infected individuals and use a simple mathematical model to quantify IL-7 effects by estimating the biological parameters of the model. We show that the increase of peripheral proliferation could not explain alone the long-term dynamics of T cells after IL-7 injections underlying other important effects such as the improvement of cell survival. We also investigate the feasibility and the efficiency of repetitions of IL-7 cycles and argue for further evaluation through clinical trials.

Table 1. Characteristics of phase I/II trials and patients included from each study.

| Characteristics                  | rh-IL-7 study [28] | INSPIRE [30] | INSPIRE 2 |
|----------------------------------|--------------------|--------------|-----------|
| Trial number                     | 2004-003772-11A    | NCT0047732   | NCT01190111 |
| Product                          | rh-IL-7 CYT 99 007 | Glyco r-hIL-7 CYT107 | Glyco r-hIL-7 CYT107 |
| Doses                            | 3, 10 μg/kg        | 10, 20, 30 μg/kg | 20 μg/kg |
| N patients enrolled              | 14                 | 26 (+6 placebo) | 23        |
| N patients analyzed*             | 14                 | 21 (+6 placebo) | 12        |
| Number of measurements of CD4 T cells per patient** | 11 | 11 | 5 |
| Number of measurements of Ki67+ CD4 T cells per patient** | 4 | 5 | 5 |
| Number of measurements of naive CD4 T cells per patient** | Na | 5 | Na |
| Number of measurements of Ki67+ naive CD4 T cells per patient** | Na | 5 | Na |
| Baseline CD4 T cells/μL**        | 230 (107; 312)     | 276 (231; 320) | 246 (200; 318) |

* Patients with complete cycles used for the model.
** Median (Interquartile range).
Na: Not applicable.
doi:10.1371/journal.pcbi.1003630.t001

Results

IL-7 induced a sustained increase of all CD4+ T cell subsets

Chronically HIV-1 infected patients with CD4+ T cell counts between 100 and 400 cells/μL and plasma HIV RNA < 50 copies (c)/mL, while on antiretroviral therapy were studied in three phase I/II trials (see Methods and Table 1 for characteristics). In Study I and II, there was a dose-dependent increase of CD4+ T cell count peaking between 14 and 21 days after the initial injection and followed by a steady decline. The peak increase ranged between 152 and 1202 CD4+ T cells/μL in the two studies [28,30]. A significant increase compared to baseline (and placebo group in Study II) persisted until 12 weeks in the first study (Figure S1) and 52 weeks in the second (Figure 1). The main contributors to CD4+ T cell increase were naive and central memory cells [28,30]. There was a transient increase of Ki67 expression (a marker of proliferation; see Methods) in all CD4+ T cell subsets during IL-7 administration (Figure 2). The peak of Ki67 expression was observed at the first available measurement after the initiation of IL-7 therapy, which is 14 days in study I and 7 days in study II. At 28 days, Ki67 expression returned to baseline in both studies.

This increase in cell proliferation, observed in parallel with the increase in CD4+ T cells, might be the only significant effect in vivo of the injection of exogenous IL-7. Indeed, IL-7 induces an acute increase of CD4+ T cell increase, followed by a slow return to baseline levels as CD4+ T cells die, explaining the observed dynamics. However, additional effects, especially on thymic output or cell survival, might exist and slow down the decline of CD4+ T cells. Recent thymic emigrants (defined as CD45RA+CD31high) and the sjβ T cell receptor excision circles (TREC) ratio (in Study II), which are both an indirect measure of thymic output [31], are significantly increased after IL-7 injections [28,30]. In Study II, we also observed a decrease in PD-1 expression (a marker of cell exhaustion) by CD4+ T cells [30] suggesting an increased cell survival. Although these observations gave some insight in
potential effects of IL-7 on T cell homeostasis, they do not quantify the respective contribution of these mechanisms to the observed CD4+ T cell dynamics in blood in terms of input and output of cells. This is why we embarked on a mathematical analysis to test whether the observed peripheral proliferation could explain the CD4+ T cell dynamics after IL-7 injections or if other additional biological mechanism played a significant role.

Mathematical modeling revealed that total CD4+ T cell dynamics are a consequence of more than a transient increase of peripheral cell proliferation

We used a simple mathematical model to investigate mechanistically the effect of IL-7 on total CD4+ and naive CD4+ T-cell dynamics (see Methods and Figure S2). Modeling CD4+ dynamics and Ki67+ expression by changing the proliferation rate during IL-
administration provided a fair fit of the data of study II (Figure 3A, plain lines). Interestingly, there was a significant linear increase of estimated proliferation rates according to the dose group (p < 0.0001; Figure 4A and 4B). However, we found a better fit of CD4+ dynamics with Model 2 (LCA = 0.173 vs. 0.937; Figure 3A, dashed lines) that includes an effect of IL-7 on proliferation rate during IL-7 administration and on loss rate after IL-7 administration. In addition to the significant dose-dependent increase of proliferation during IL-7, we estimated a decrease of the loss rate of quiescent cells from 0.061 to 0.044–0.049 per day corresponding to an improvement of the life span of about 25% from 16.4 days to 20.4–22.7 days (likelihood ratio test p-value < 0.001; Figure 4, Table 2 and Table S1). This result was found with both formulation of IL-7 (with either rh-IL-7 or glycosylated rh-IL7; Table S2). Adding a modification of the constant production of CD4+ (Model 3) rather than a modification of loss rate (Model 2) did not substantially improve the fit to total CD4+ T cell dynamics as shown in Figure 3A where the fits from the two models overlap (see also Figure S3 and S4). In other words, although the Model 2 that includes a modification of quiescent cell loss rate was better from a statistical point of view (LCA = 0.131 vs. 0.173), it was difficult to distinguish the fits of the two models. Interestingly, all models described correctly the initial increase of CD4+ T cells and thereafter, Model 1 predicted a slower decline of CD4+ T cells than Model 2 and 3. This poorer long-term fit might be explained by a transient effect on the proliferation rate (until day 16) that altered only briefly the equilibrium while the lingering effect on the production or loss rate changed it in the long-term.

Figure 2. Increase of percentage of Ki67+ among CD4+ T cells (A), naive (CD45RA+CD27+CCR7+) CD4+ T cells (B); total CD4+Ki67+ cell counts (C) and naive CD4+Ki67+ cell counts (D) for INSPIRE Study (Study II) depending of the dose. Observed median percentage of Ki67+ among CD4+ T cells by group: placebo (crosses), 10 µg/kg (triangles), 20 µg/kg (squares) and 30 µg/kg (diamonds). Red arrows indicate IL-7 administration. Error bars and other statistical analyses are provided in Levy et al. [30].

doi:10.1371/journal.pcbi.1003630.g002
To further analyze the potential effect of IL-7 on thymic output, we explored the effect of IL-7 on the naive (CD45RA\(^+\)CD27\(^+\)) CD4\(^+\) cells (either Ki67\(^+\) or Ki67\(^-\)) using the available data for this subset (until 12 weeks). Here again, we found that an additional effect of IL-7 after its administration either on the thymic production or the loss rate significantly improves the fits compared to a model including only an effect on the proliferation rate (Table S3). Interestingly, we found that the best model was the one including an effect on the thymic production rate of naive cells after IL-7 administration in addition to the proliferation rate (LCVa = 1.705 vs. 1.760 for the model including an effect on the loss rate after IL-7 administration; Table 2 and Table S3). Both models including an additional effect of IL-7 were better than the model with an effect on proliferation only (LCVa = 1.832). However, a change in loss rate of quiescent cells led to a good fit as well and individual fits from Model 2 and 3 were very close as shown in Figure 3B and S5.

Finally, we were interested in the ability of Model 2 (with the effect of IL-7 on proliferation and loss rates) to predict individual responses to IL-7. We made use of data from 12 additional patients (from INSPIRE 2, Table 1) treated with a 20 μg/kg dose as per the INSPIRE study. We used only the first two measurements of total CD4\(^+\) T cells and Ki67\(^+\) cells to compute the Empirical Bayes estimates for each parameter that could vary between patients. The other population parameters were fixed according to the previous estimations (Table S1). We then predicted the individual CD4\(^+\) T cell dynamics until week 12. Most of the observed total CD4\(^+\) T cell counts were in the prediction interval (Figure S6). Therefore, the model that includes an effect of IL-7 on proliferation and loss rates led to a good description of the total CD4\(^+\) T cell dynamics and a fair predictive ability at the individual level.

**Potential for IL-7 to achieve sustained CD4 restoration with repeated administration**

To our knowledge, no data exists yet on the effect of repeated cycles of IL-7 in vivo. Therefore, to investigate to what extent IL-7 administration might sustain CD4\(^+\) T-cell restoration, we artificially created data and compared different scenarios allowing the IL-7 effect to wane after subsequent injections compared to the initial one (see Methods). In this part, we considered an extended version of the mathematical model that incorporates a homeostatic proliferation (see Methods). This model gave similar results as presented in the previous section (not shown) but more realistic long-term dynamics for repeated IL-7 administrations (total CD4\(^+\) T cell counts staying below 1500 cells/μL).
As the dose 20 mg/Kg was the one recommended for further phase II/III studies [30], we simulated CD4\(^+\) T cell dynamics with hypothetical repeated cycles of IL-7 administration for each patient who received this dose in the Study I (INSPIRE): namely 14 patients. The parameter \(k\) controlling the proliferation rate was fixed to the same value for each patient (see Methods). The initial
Modelling IL-7 Effect in HIV Infected Patients

CD4+ dynamics was the one predicted by the Model 2 as presented in the previous section. CD4+ T cell count were assumed to be measured every three months and when it dropped below 500 cells/μL a cycle of IL-7 administration was simulated (one injection per week for 3 weeks). The dynamics were therefore based in part on fit to observed data and in part on a predicted response to repeated therapy. We analyzed two primary outcomes: the time spent above 500 cells/μL and the number of cycles (including the first cycle) needed to maintain CD4+ T cell counts above 500 cells/μL over 2 years. A secondary outcome was the median time between two successive cycles.

Simulations were performed according to several scenarios varying from a constant effect after each cycle and decreasing effects on loss and proliferation rates. At each cycle, we assumed that the effect of IL-7 on the loss rate of CD4+ T cells started to decrease 3 (or 9) months after the last injection and disappeared after 1 (or 2) year. Table S3 shows some scenarios ordered from the best to the worst according to the primary outcomes. Where all cycles (around 9

| Table 2. Estimates of the “best” model for total CD4+ and naive CD4+ T-cell dynamics in Study II (INSPIRE Study). |
|--------------------------------------------------------|-------------------|-------------------|
| Production Rate | Total CD4 | Naive CD4 |
| --- | --- | --- |
| before & during IL7 | 9.849 (2.126) | 3.600 (1.518) |
| (μ+, cells/day) | 10 μg/kg | 9.849 | 4.904 (2.883) |
| 20 μg/kg | 9.849 | 6.619 (3.347) |
| 30 μg/kg | 9.849 | 8.935 (3.885) |
| Proliferation Rate | before & after IL7 | 0.027 (0.004) | 0.004 (0.001) |
| (μp, /day) | during IL7 | 0.107 (0.026) | 0.068 (0.003) |
| 20 μg/kg | 0.129 (0.032) | 0.105 (0.003) |
| 30 μg/kg | 0.156 (0.039) | 0.161 (0.004) |
| Loss rate of non-proliferating cells | before & during IL7 | 0.061 (0.010) | 0.050 (0.019) |
| (μQ, /day) | after IL7 | 0.049 (0.008) | 0.050 |
| 20 μg/kg | 0.046 (0.008) | 0.050 |
| 30 μg/kg | 0.044 (0.007) | 0.050 |
| Loss rate of proliferating cells (μP, /day) | 0.070 (0.031) | 0.078 (0.039) |
| Reversion rate to quiescent state (μR, /day) | 1.213 (0.173) | 1.199 (0.255) |
| σQ* | −0.205 (0.066) | 0.523 (0.132) |
| σR* | 0.396 (0.165) | 0.458 (0.308) |

Bold-italic numbers represent significant IL-7 effects. Standard-errors are given between brackets. Parameters for the other models and other studies are presented in Supplemental Materials.

Note that the random effects were on the log-transformed parameter and not on the natural scale.

Discussion

We report here a mathematical analysis of total and naive CD4+ T cell dynamics in HIV-1 infected patients treated with antiretrovirals who experienced a significant increase of CD4+ T cell counts while receiving IL-7 therapy. We confirm, once again, that IL-7 induces a significantly increased peripheral proliferation of CD4+ T cells as measured by Ki67 expression. However, results presented here extend our knowledge on the in vivo effects of IL-7 by showing that this increased peripheral proliferation alone could not explain the long-term changes in CD4+ T cell number that were observed. An increase of the production rate of naive CD4+ T cells and a decrease of the loss rate for total CD4+ T cells might also contribute to T-cell homeostasis during IL-7 therapy. Importantly, baseline parameters such as naïve T cell production (around 9×10^6 naive cells/day) [32], loss rate of proliferating cells (0.08 day^-1) [33] or reversion rate (accounting for duration of division and duration of Ki67 expression) were in agreement with current knowledge. Furthermore, our mathematical model shows good performance for individual predictions and provides insights on the feasibility of repeated cycles of IL-7 (or long-lasting formulation) for maintaining CD4+ T cell counts in HIV-infected
patients. Predictions from the mathematical model underline the importance of an additional effect of IL-7 beyond peripheral cell proliferation for long-term CD4\(^+\) T cell responses. HIV infection leads to a profound disturbance of T cell homeostasis with an increased turnover of these cells [33–35]. The naive T cell pool is replenished mainly by post-thymic proliferation in adults [36,37] but the observed proliferation of naive CD4\(^+\)T cells is not enough to prevent the slow decline of these cells in HIV infected patients. Augmenting immunity with exogeneous cytokines has been attempted in HIV infection; and although CD4 T cell numbers were increased with administration of IL-2, two large clinical trials failed to show any evidence of clinical benefit [38]. The failure of IL-2 therapy to confer clinical benefit despite CD4 T cell increases could be attributed at least in part to the regulatory phenotype of the expanded cells [39] and the possibility of enhanced inflammation and coagulation during administration [40]. The effects of IL-7 on the other hand are fundamentally different [13] and the defined role of IL-7 in maintaining T cell homeostasis in health provides rationale for testing its therapeutic administration in HIV infection complicated by immune failure [41].

Our data argue for an increase in cell survival after IL-7 administration. Our results show that CD4\(^+\)T cell dynamics are better explained by a decrease of cell loss in addition to the transient peripheral proliferation. This finding is consistent with previous findings that increasing cellular survival through up-regulation of bcl2 expression is a physiological function of IL-7 [13,42]. Moreover, increases in T cell survival after IL-7 injection have been demonstrated in monkeys using BrdU labeling [15]. Our findings warrant further study to define the precise mechanisms of IL-7 induced cell expansion in HIV infection.

Improvement of thymopoiesis has been reported during exogenous IL-7 administration [5,6]. However, there is some controversy on the importance of this effect in vivo [9,43]. Sportes et al. showed a modest increase of absolute numbers of TREC\(s\) and a major dilution of TREC content due to peripheral cell proliferation leading to the conclusion that the increase of TGR repertoire diversity is mainly due to the proliferation of recent thymic emigrants. The effects of IL-7 on thymopoiesis may be dependent, on one hand, on the underlying disease (HIV-1 infection, cancer and chemotherapy) and, on the other hand, on the duration of cytokine therapy [9]. In our simulations of repeated IL-7 cycles, we did not consider any effect of IL-7 on thymopoiesis because we favoured the hypothesis of an effect on cell survival according to the rationale above and the slightly better fit. Therefore, if IL-7 administration improved thymopoiesis in addition to peripheral proliferation and enhanced cell survival, the CD4\(^+\) T cell response should have surpassed our predictions.

---

**Figure 5.** Simulated trajectories of CD4\(^+\) T cell dynamics over 2 years for patient #1 with repeated IL-7 injections. Simulated treatment is based on CD4\(^+\) T cell count measurements (Triangles are the observed values) every three months (grey dashed vertical lines). If the count drops below 500 cells/\(\mu\)L, a new cycle of three IL-7 injections is simulated (single black vertical lines). A. Effect on both proliferation and loss rate of non-proliferating cells was full and constant during subsequent IL-7 cycles (scenario A-1 and A-2, see Table S4). B. The effect on proliferation during repeated cycles was assumed to be 50% of the one of the first cycle while the effect on loss rate was unchanged (scenario B-1 and B-2, see Table S4). Other parameters are presented in Table S1 (Model 2, dose 20), \(k = 0.176\).

doi:10.1371/journal.pcbi.1003630.g005
For long-term predictions using simulations, the initial model was extended by adding a homeostatic control of proliferation after IL-7 administration. This can be related to the modulation of IL7Ra expression that prevents uncontrolled proliferation [44,45]. Furthermore, the effect on T cell loss was also modeled to wane over time. Strikingly, the estimation of the duration of the effect of IL-7 on cell survival was prolonged up to 2 years. Likely, this could not be explained by the pharmacokinetics of exogenous IL-7 that was administered during two weeks only. However, exogenous IL-7 is known to bind to components of the extracellular matrix resulting in saturation of this tissue compartment followed by a slow release of IL-7, which may exert long-lasting effects [3]. Also, IL-7 could have persistent effects on cellular homeostasis by normalizing tissue architecture through decreasing fibrosis in the gut [46] and in lymph nodes [23,47,48,49] and thus improving cellular access to survival signals. Other potential activities such as effects on cell trafficking [27,50], IL-7 antibody formation, switch to memory phenotypes [14,51] or impact on proviral HIV DNA content [52] have not been taken into account in this model. Redistribution of CD4+ T cells to tissues, leading to a transient decrease of CD4+ T cells levels in blood, is mainly observed in the first days after IL-7 administration and should not affect measurements made thereafter. Although neutralizing anti-IL-7 antibodies were not observed in patients following the first cycle of IL-7 [28], their induction after repeated administration could attenuate the effects that we modeled here. For these reasons, new clinical trials are needed to help distinguishing the persistent IL-7 effect(s) involved in CD4 recovery in HIV-infected patients and to propose personalized therapy in the future [53]. Furthermore, we assumed repetition of cycles (i.e. three injections over two weeks) but the repetition of single injections could lead to similar results shown in the simulations if the effect of one injection respect the assumptions made in some scenarios. For instance, the repetition of a single injection may have a reduced effect on proliferation and cell survival compared to a whole cycle but this would still lead to a good maintenance of CD4+ T cell counts.

There are limitations to this study that include the restricted number of harvest times and the lack of validated markers for cellular lifespan. One way to overcome these limitations and to help distinguishing between increased production and increased survival is to perform studies that include in vivo labeling with deuterium and TREC content measurements. Indeed, deuterium labeling is a recent and powerful tool to estimate cell turnover [54] and used in combination with TREC content allows estimation of thymic output [37,55]. Also, it may have been relevant to distinguish the dynamics in lymph node tissue to better capture the long-term effect of IL-7 although data on lymph node tissue would be difficult to obtain. Despite these caveats, the goodness of fit and the predictive capacity of the model provide important insights for further development of IL-7 treatment strategies. We have learned that IL-7 administration leads to a burst of peripheral proliferation that is likely associated with a lingering effect beyond the period of IL-7 administration. We surmise that a durable effect of IL-7 on T cell homeostasis could be achieved after repeated administration but safety and activity need to be confirmed [2,3].

### Materials and Methods

#### Subject population and trial design

Data were generated in three phase I/II studies (Table 1). All participating institute’s Institutional Review Boards approved the studies and the procedures and all participants provided written informed consent before study participation. The rh-IL-7 study (referred to as Study I) [28] evaluated Recombinant Human Interleukin 7 (rh-IL-7), a nonglycosylated protein composed of 153 amino acids, and included 14 HIV-infected patients receiving antiretroviral therapy whose CD4+ T cell counts were between 100 and 400 cells/µl and whose plasma HIV RNA levels were less than 50 copies/ml. Patients received a total of 8 subcutaneous injections of 2 different doses of recombinant human IL-7 (3 or 10 µg/kg, dose 1 and 2, respectively) 3 times per week over a 16-day period. Eleven repeated measurements of total CD4+ T cells up to 48 weeks and four measurements of Ki67+ positive T cells among CD4+ T cells up to 12 weeks were performed.

The INSPIRE Study (referred to as Study II) [30] evaluated 3 weekly subcutaneous (SC) injections of a purified glycosylated 152 amino acid rhIL-7 (Cyt107 over a period of 2 weeks). Three doses were tested: 10, 20 and 30 µg/Kg/week. Seven, 8 and 6 patients received three injections (one per week) in each dose group, respectively. Two HIV-infected patients were randomized per dose level and received a placebo (NaCl). Visits for safety and immunologic evaluation were performed at days 7, 14, 21, 28, 35, week 9 and week 12 and then quarterly up to week 52. In the INSPIRE 2 Study (referred to as Study III), 12 patients received 3 subcutaneous injection of 20 µg/Kg/week Cyt107 (one per week over 2 weeks) and were followed up to week 52.

#### Flow cytometry

Absolute CD4 T-cell counts, T cell expression of Ki67, and the proportions of naïve subsets defined by expression of CD45RA and CD27 (naïve: CD45RA-CD27+) were measured in whole blood by flow cytometric assays within 6 hours of blood draw in the Rh-IL7 study [28]. In INSPIRE, naïve cells in cryopreserved samples were identified by expression of CD45RA, CD27 and CCR7; in INSPIRE 2 naïve cells were enumerated in cryopreserved PBMC by expression of CD45RA and CCR7.

#### Mathematical model for the estimation of IL-7 effect

Ki67 is a cellular marker of proliferation [36] and is associated with cell proliferation. It is present during all active phases of the cell cycle (namely G1, S, G2 and M) and it is absent from resting cells (phase G0). Therefore, some of the cells expressing Ki67 are actually in the division phase M and the rest are “on their way” to this phase or very recently in this phase. In this model, we assume that proliferating cells express Ki67 whereas non-proliferating (i.e. resting) cells do not; this is a relatively good approximation. We consider the following mathematical model including two populations of cells (see Figure S2 for a general cartoon of the model): non-proliferating cells (Ki67+, denoted Q) and proliferating cells (Ki67+, denoted P):

\[
\frac{dQ}{dt} = \lambda + 2\rho P - \mu_Q Q - \pi Q
\]

\[
\frac{dP}{dt} = \pi Q - \rho P - \mu_P P
\]

Non-proliferating cells Q are produced at a constant rate \( \lambda \). They become Ki67+ at rate \( \pi \) and die at rate \( \mu_Q \). Proliferating cells (P) die at rate \( \mu_P \) and lose their proliferation marker Ki67 at rate \( \rho \) (cells express Ki67 for 1/\( \rho \) days). We assumed that 2P cells enter the Q compartment that is two daughter cells are produced after one single cell cycle. The loss rates (\( \mu_P \) and \( \mu_Q \)) are influenced by cell survival but also by any redistribution between blood and other tissues. Before the first injection at \( t = 0 \), both populations are assumed to be at equilibrium (i.e. \( dQ/dt = 0 \) and \( dP/dt = 0 \)). This model was used for total CD4+ T-cells where Q and P include
both naive and memory CD4+ T-cells. Similarly, we used this general model to describe naive CD4+ T-cell dynamics adding a superscript ‘N’ to all parameters ($k$, $\pi$, $\mu_N$, $N$, $p$, $\rho$) and where $Q_N$ represent non-proliferating naive CD4+ T-cells and $P_N$ proliferating naive CD4+ T-cells.

To model the effect of IL-7, we considered different models allowing some parameters to change over time (i.e. during or after the IL-7 administration). We distinguished three models:

- **Model 1** includes only an effect on the proliferation rate $\pi$ during the IL-7 administration.
- **Model 2** includes an effect on $\pi$ and an additional effect on the loss rate of non-proliferating cells $\mu_Q$ (effect tested during or after the IL-7 administration).
- **Model 3** includes an effect on $\pi$ and an additional effect on the production rate $\lambda$ (effect tested during or after the IL-7 administration).

Models including an effect of IL-7 on the duration of Ki67 expression or on a direct production of Ki67+ cells from the thymus were also tried but did not improve the fit of the data (not shown).

Each parameter is assumed equal to a baseline value (denoted $\pi_0$, $\mu_Q$, $\lambda_0$) and we tested a possible effect of IL-7 and a possible dose effect. For instance, the proliferation rate $\pi$ was assumed equal to $\pi = \pi_0$ before ($t = 0$) and after IL-7 administration ($t > 0$) and $\pi = \pi_0 + \pi_1 trt + \eta_1 dose$ during IL-7 administration ($0 < t < T$). The variable $\delta_0$ indicates if an individual received the placebo ($\delta_0 = 0$) or IL-7 injections ($\delta_0 = 1$), hence the parameter $\eta_0$ represents the possible effect of IL-7 on the parameter $\pi$. Similarly, we tested a possible dose effect via the parameter $\eta_1$ and the variable dose effect: $\delta_0 \equiv 0$ if the individual received the placebo and 0.3, 1, 2 or 3 according to the received dose of IL-7. The additional dose effect is here assumed to be linear: the dose 30 $\mu$g/Kg will have 3 times more effect than the dose 10 $\mu$g/Kg and 10 times more than the dose 3 $\mu$g/Kg. The time $t$ (time of IL-7 effect on the proliferation rate $\pi$) was fixed to 16 days and robustness analyses with values between 14 and 16 days have been performed leading to similar results but slightly worse likelihood (not shown).

**Mathematical model of successive IL-7 injections**

For the simulations of repeated administrations of IL-7, a homeostatic control of proliferation was incorporated in order to constrain the CD4+ T cell level in a credible range (below 1500 cells/$\mu$L). The newly defined rate of proliferation, denoted $\pi^*$, is defined as follows:

$$\pi^* = k_{\text{feedback}} \pi = \left[ \frac{N_0}{N_T} \right]^\kappa \pi,$$

where $N_0$ is the baseline CD4+ T cell count, $N_T$ is CD4+ T cell count at time $t$ and $\kappa$ is a number lower than 1 estimated on the data. As $N_0$ is relatively low due to lymphopenia, cells will be allowed to proliferate more while the circulating number of CD4+ T cells is still relatively low but as soon as this number deviates too much from the baseline value the proliferation rate is reduced [57]. Several formulations have been tested, including one with $N_{\text{max}} = 1000$ referring to a normal healthy value rather than $N_0$ and all formulations led to similar conclusions due to different estimates of the parameter $\kappa$ (not shown). The parameter $\kappa$ was estimated by profile likelihood because it was difficult to estimate it at the same time as the other parameters. The parameter $\kappa$ was therefore fixed at different plausible values and the model was estimated for each value of $\kappa$ and we kept the value of $\kappa$ for which the model had the lowest likelihood.

Here, we only considered Model 2 including the effect of IL-7 on the proliferation rate and the loss rate of non-proliferating cells as it was the best model according to real data. Moreover, in this model, the loss rate of non-proliferating cell ($\mu_Q$) was assumed decreased (to a constant value) after day 16 and during ($T_{\text{end}}$;16) days after the injection and then linearly increased to its baseline value after $T_{\text{end}}$ days (see Figure S2). As subsequent cycles of IL-7 might have reduced effects compared to the first one, the proliferation rate (resp. loss rate) of the subsequent cycle is denoted by $\pi_{\text{sub}}$ (resp. $\mu_{\text{sub}}$) and keep $\pi$ (resp. $\mu_Q$) for the first injection. These rates are defined as $\pi_{\text{sub}} = \pi_n$ and $\mu_{\text{sub}} = \mu_n$ where $\pi_n$ and $\mu_n$ represent the strength of new IL-7 administration (i.e. the percentage of effect of $\pi_{\text{sub}}$ and $\mu_{\text{sub}}$ compared to the initial injection). Therefore, we assumed for all subsequent cycles a similar reduction of IL-7 effects compared to the first cycle.

**Statistical methods**

Parameters were estimated using maximum penalized likelihood that takes into account unbalanced data due to sparse missing values and the availability of Ki67+ staining up to week 12 (no measurements were available beyond that time). This method can be viewed either as a version of maximum likelihood allowing taking into account prior knowledge (from previous estimates found in published studies), or as an approximation of Bayesian inference [58,59].

The Ordinary Differential Equations (ODE) system was solved with dsolve from the ODEPACK [60] for stiff system using Backward Differentiation Formula (BDF) methods (the Gear methods). Each parameter ($\theta_i$) was modeled as the sum of a population (fixed) parameter ($\beta$) and a random effect ($b_i$) allowing the parameter to be different from one patient to another: $\theta_i = \beta + b_i$. Each random effect was assumed to be normally distributed with a variance to be estimated: $b_i \sim N(0, \sigma^2)$. A stepwise selection procedure was used and when the variance of a given random effect was not significant, the parameter was considered as fixed in the next model. We observe the number of proliferating cells ($\mathcal{P}$) and the total number of cells ($\mathcal{P} + \mathcal{Q}$) plus a measurement error adding two unknown parameters $\sigma_{\mathcal{P}}$ and $\sigma_\mathcal{Q}$. The final models included only two random effects, one for $\lambda$ (production rate) and one for $\rho$ (the rate at which proliferating cells go back to rest). The best model was selected using an approximation of the likelihood cross-validation criterion (LCVa, [58,59]) that is based on the likelihood weighted by the number of parameters estimated like the Akaike Criteria (AIC). The lower is the value of the criteria the better is the model. Individual predicted trajectories were computed using the Parametric Empirical Bayes (PEB) for all parameters having a random effect [61].

**Supporting Information**

**Figure S1** Dose-dependent increase of total CD4+ T cell count (A), Ki67+CD4+ T cells count (B) and percentage of CD4+ T cells expressing Ki67 (C) for Study rh-IL7 (Study I). Observed median count in cells/$\mu$L by group: 3 $\mu$g/kg (black dots) and 10 $\mu$g/kg (grey dots). Error bars and other statistical analyses are provided in Levy et al. (2009). (DOC)

**Figure S2** Graphical representation of the biological model (A) and changes of the loss rate over time after the first IL-7 cycle (B). After the first cycle, the potential effect of IL-7 might be reduced and results in a higher level of $\mu_Q$ between day 16 and day $T_{\text{end}}$. In the simulation study, we considered two
sets of values for $T_{\text{full}}$ and $T_{\text{rest}}$, namely $(T_{\text{full}} = 90, T_{\text{rest}} = 365)$ and $(T_{\text{full}} = 270$ and $T_{\text{rest}} = 731)$.

Figure S3  Goodness of fit of total CD4$^+$ T cell count from rh-IL-7 Study (Study I) for the three different models. The prediction from model 1 assuming only an effect of IL-7 on the proliferation rates is in solid line, from Model 2 assuming an effect on proliferation rate and on the loss rate of resting cells in dashed line and from Model 3 assuming an effect on proliferation rate and on the thymic production in dotted lines. Note that the estimated trajectories from Model 2 and 3 almost overlap.

Figure S4  Goodness of fit of total CD4$^+$ T cell count from INSPIRE Study (Study II) for the three different models. The prediction from model 1 assuming only an effect of IL-7 on the proliferation rates is in solid line, from Model 2 assuming an effect on proliferation rate and on the loss rate of resting cells in dashed line and from Model 3 assuming an effect on proliferation rate and on the thymic production in dotted lines. Note that the estimated trajectories from Model 2 and 3 almost overlap.

Figure S5  Goodness of fit of naive CD4$^+$ T cell count from INSPIRE Study (Study II) for the three different models. The prediction from model 1 assuming only an effect of IL-7 on the proliferation rates is in solid line, from Model 2 assuming an effect on proliferation rate and on the loss rate of resting cells in dashed line and from Model 3 assuming an effect on proliferation rate and on the thymic production in dotted lines. Note that the estimated trajectories from Model 2 and 3 almost overlap.

Figure S6  Predicted dynamics of total CD4$^+$ T cell count for the 9 first patients from Study III (INSPIRE 2). Dynamics were predicted using Model 2, assuming an effect of IL-7 on proliferation and loss rate of non-proliferating cells after the IL-7 administration. The first two measurements (at the left side of the vertical line) were used to compute the individual parametric empirical bayes. The dynamics at the right side of the vertical line were predicted without using measurements subsequent to the first two. 95% measurement error confidence intervals are represented by dashed lines.

Figure S7  Median percentages of time spent above 500 cells/μL and median numbers of cycles over a 24 month follow-up. For the simulations of repeated administrations of IL-7, we assumed that injections might have reduced effects compared to the first one of $1-\sigma_d/\sigma_d$ and $1-\sigma_p/\sigma_p$.

Table S1  Estimates of model parameters for total CD4$^+$ and CD4$^+$Ki67$^+$ T-cell dynamics in Study II (INSPIRE Study). Model 1: only the proliferation rate ($\pi$) is modified; Model 2: proliferation rate ($\pi$) and loss rate ($\mu_Q$) of non-proliferating cells are modified; Model 3: proliferation rate and constant production rate ($\lambda$) are modified. All IL-7 effects underlined in grey were statistically significant at 0.05 level. Standard-errors are given between brackets.

Table S2  Estimates of model parameters for total CD4$^+$ and CD4$^+$Ki67$^+$ T-cell dynamics in Study I (rh-IL-7 study). Model 1: only the proliferation rate ($\pi$) is modified; Model 2: proliferation rate ($\pi$) and loss rate ($\mu_Q$) of non-proliferating cells are modified; Model 3: proliferation rate and constant production rate ($\lambda$) are modified. All IL-7 effects underlined in grey were statistically significant at 0.05 level. Standard-errors are given between brackets.

Table S3  Estimates of model parameters for naive CD4$^+$ and naive CD4$^+$Ki67$^+$ T-cell dynamics in Study II (INSPIRE Study). Model 1: only the proliferation rate ($\pi$) is modified; Model 2: proliferation rate ($\pi$) and loss rate ($\mu_Q$) of non-proliferating cells are modified; Model 3: proliferation rate and constant production rate ($\lambda$) are modified. All IL-7 effects underlined in grey were statistically significant at 0.05 level. Standard-errors are given between brackets.

Table S4  Percentage of time spent above 500 cells/μL, number and median time between cycles according to various scenarios.

Acknowledgments

This work was presented in part at the 17th Conference of Retroviruses and Opportunistic Infections in San Francisco, California, USA, on February 27–March 2, 2010, and at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy in Boston, Massachusetts, USA, on September 12–15, 2010.

We would like to thank Michele Di Mascio for his valuable comments on an earlier draft of the manuscript. Parallel computing was used thanks to the computing facilities MCIA (M"ecoscentre de Calcul Intensif Aquitain) of the Universit"e de Bordeaux and of the Universit"e de Pau et des Pays de l’Adour.

Author Contributions

Performed the experiments: CL SB RPS. Analyzed the data: RT JD MP AJ. Wrote the paper: RT JD MP YL CL SB AJ TC RPS MML IS. Designed clinical trials: TC RPS MML IS YL. Designed the study: RT JD DC YL.

References

1. Lange CG, Lederman MM (2003) Immune reconstitution with antiretroviral therapies in chronic HIV-1 infection. Journal of Antimicrobial Chemotherapy 51: 1–4.
2. Fry TJ, Mackall CL (2002) Interleukin-7: from bench to clinic. Blood 99: 3892–3904.
3. Mackall CL, Fry TJ, Gress RE (2011) Harnessing the biology of IL-7 for therapeutic application. Nature Reviews Immunology 11: 330–342.
4. Mackall CL, Fry TJ, Bare C, Morgan P, Galbraith A, et al. (2001) IL-7 increases both thymic-dependent and thymic-independent T-cell regeneration after bone marrow transplantation. Blood 97: 1491–1497.
5. Bolotin E, Snogorzevska M, Smith S, Widmer M, Weinberg K (1996) Enhancement of thymopoiesis after bone marrow transplant by in vivo interleukin-7. Blood 98: 1887–1894.
6. Okamoto Y, Douek DC, McFarland RD, Koup RA (2002) Effects of exogenous interleukin-7 on human thymus function. Blood 99: 2851–2858.
7. Soares MV, Borthwick NJ, Maini MK, Janossy G, Salmon M, et al. (1998) Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity and naive CD4$^+$ T-cell subsets. Journal of Experimental Medicine 205: 1701–1714.
29. Camargo JF, Kulkarni H, Agan BK, Gaitan AA, Beachy LA, et al. (2009)

28. Levy Y, Lacabaratz C, Weiss L, Viard JP, Goujard C, et al. (2009) Enhanced T

26. Fry TJ, Moniuszko M, Creekmore S, Donohue SJ, Douek DC, et al. (2003) IL-7

24. Juffroy O, Bugault F, Lambotte O, Landires I, Viard JP, et al. (2010) Dual

23. Zeng M, Smith AJ, Wietgrefe SW, Southern PJ, Schacker TW, et al. (2011)

22. Shive CL, Mudd JC, Funderburg NT, Sieg SF, Kyi B, et al. (2014) Inflammatory

32. Bains I, Thiebaut R, Yates AJ, Callard R (2009) Quantifying thymic export:

14. Kondrack RM, Harbertson J, Tan JT, McBreen ME, Surh CD, et al. (2003)

11. Tan JT, Dudl E, LeRoy E, Murray R, Sprent J, et al. (2001) IL-7 is critical for

59. Prague M, Commenges D, Guedj J, Drylewicz J, Thiebaut R (2013) NIMROD:

56. Scholzen T, Gerdes J (2000) The Ki-67 protein: from the known and the

55. Kovacs JA, Lempicki RA, Sidowov IA, Adelberger JW, Herpin B, et al. (2001)

53. Prague M, Commenges D, Thiebaut R (2013) Dynamical models of biomarkers

52. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, et al. (2009) HIV

49. Onder L, Narang P, Scandella E, Chai Q, Iolyeva M, et al. (2012) IL-7-

47. Huang M, Sharma S, Zhu LX, Keane MP, Luo J, et al. (2002) IL-7 inhibits

44. Park JH, Yu Q, Erman B, Appelbaum JS, Montoya-Durango D, et al. (2004)

46. Hodge JN, Srinivasulu S, Hu Z, Read SW, Porter BO, et al. (2011) Decreases in IL-7 levels during antiretroviral treatment of HIV infection suggest a primary role of IL-7 in the deletion process of T-cells in HIV-infected individuals.

42. Vivien L, Benoist C, Mathur D (2001) T lymphocytes need IL-7 but not IL-4 or IL-6 to survive in vivo. International Immunology 13: 763–768.

41. Reynolds J, Coles M, Lythe G, Molina-Paris C (2013) Mathematical Model of Naive T Cell Division and Survival IL-7 Thresholds. Frontiers in Immunology 4: 194.

40. Storeck, Gilleppeg, T, 3rd, Lu H, Joseph A, Dawson MA, et al. (2005) Interleukin-7 improves CD T cell recovery and stimulates autologous CD34 cell transplantation in non-human primates.

39. Park, JH, Yu Q, Erman B, Appelbaum JS, Montoya-Durango D, et al. (2004) Suppression of IL-7/Ralphi transcription by IL-7 and other prosurvival cytokines: a novel mechanism for maximizing IL-7-dependent T cell survival. Immunity 21: 289–302.

38. Mazzucchelli R, Durum SK (2007) Interleukin-7 receptor expression: intelligent design. Nature Reviews in Immunology 7: 144–154.

37. Serei I, Estes JD, Thompson VW, Al-Jalbout DR, Fisch MA, et al. (2014) Decreases in colonic and systemic inflammation in chronic HIV infection after IL-7 administration. PLoS Pathogens 10: e1003980.

36. Meier D, Bornmann C, Chappaz S, Schmutz S, Otten LA, et al. (2007) Ectopic lymphoid-organ development occurs through interleukin-7-mediated enhanced survival of lymphoid-tissue-induced cells. Immunity 26: 643–654.

35. Onder L, Narang P, Scandella E, Chai Q, Iolyeva M, et al. (2012) IL-7-producing stromal cells are critical for lymph node remodeling. Blood 120: 4673–4683.

34. Hellerstein M, Hanley MB, Cesar D, Siler S, Papageorgopoulos C, et al. (1999) Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nature Medicine 5: 83–89.

33. Kass RE, Steffey D (1989) Approximate Bayesian inference in conditionally independent hierarchical models (parametric empirical Bayes models). Journal of the American Statistical Association 84: 717–726.